Cardiac Dimensions Secures $53M Series E Financing to Advance Carillon Mitral Contour System for Heart Failure Patients with Functional Mitral Regurgitation

I. Financing Highlights: Capital Boosts Innovation in Heart Failure Treatment

Recently, Cardiac Dimensions successfully completed a striking $53 million Series E financing round, led by Ally Bridge Group, with active participation from new investor Claret Capital Partners, and increased investment from existing investors, resulting in an oversubscribed round.This significant move has brought the company's total financing to over 200 million US dollars., injecting strong momentum into its continuous innovation and development in the field of heart failure treatment.

These funds have clear and critical uses. On one hand, they will fully support the completion of the pivotal U.S. EMPOWER trial.This trial is crucial for evaluating the safety and efficacy of the Carillon Mitral Contour System in treating heart failure patients, and is expected to provide stronger clinical evidence for this therapy.On the other hand, the funds will support the ongoing commercialization of the Carillon Mitral Contour System. This system is designed to treat heart failure patients with early-stage functional mitral regurgitation (FMR) by restoring the natural function of the valve and promoting favorable left ventricular remodeling. The acceleration of its commercialization will enable more patients to benefit from this innovative therapy.

From a strategic perspective, this financing is of far-reaching significance. It fully demonstrates the investors' firm confidence in Cardiac Dimensions' non-invasive mitral valve repair technology.In the field of heart failure treatment, functional mitral regurgitation is a common and challenging issue that significantly impacts patients' quality of life and survival rates.The Carillon system offers a new approach to addressing this challenge. Its unique design and therapeutic principles bring new hope to patients. The active participation of investors also highlights the urgent need for innovative treatment solutions in this field, as well as its significant market potential. With the intensification of population aging, the number of heart failure patients continues to rise, leading to an increasing demand for effective treatment methods. Against this backdrop, Cardiac Dimensions, Inc. has secured substantial financing, which is expected to spark a revolution in the field of heart failure treatment and guide the industry toward a new direction.

2. Carillon System: A Disruptive Mitral Valve Repair Solution

1. Technological Breakthrough

Carillon Mitral Contour System Achieves Significant Technological Breakthrough with Its Core in Innovative Indirect Annuloplasty. This technology ingeniously utilizes the anatomical structure of the coronary sinus vein to anchor the device, reshaping the mitral valve annulus to reduce mitral regurgitation. The brilliance of this design lies in its ability to effectively repair and improve mitral valve function without directly contacting or damaging the mitral valve leaflets. Compared with traditional mitral valve repair techniques, it avoids damage to the valve leaflets, significantly reducing surgical risks and the probability of postoperative complications. In traditional surgeries, manipulation of the valve leaflets may lead to severe issues such as leaflet tearing or perforation, whereas the Carillon system fundamentally avoids these risks, offering patients a safer and more reliable treatment option.

From the perspective of surgical operation, the minimally invasive advantages of the Carillon system are extremely significant. It adopts the transjugular approach, which has the characteristics of less trauma and faster recovery compared to traditional open-chest surgery. The surgical procedure can be completed in about 1 hour without general anesthesia. This not only reduces the patient's pain during the operation but also lowers the risks associated with anesthesia. For patients in poor physical condition who cannot tolerate general anesthesia and open-chest surgery, the Carillon system is undoubtedly a blessing. This minimally invasive approach also reduces the difficulty of the surgical operation, allowing more medical institutions and doctors to perform related treatments, thereby improving treatment accessibility.

2. Clinical Value

In clinical applications, the Carillon system has demonstrated outstanding value. A large amount of clinical research data strongly supports its significant efficacy. Taking the CINCH-FMR study as an example, this research conducted long-term follow-ups on numerous patients. The results showed that up to 58.4% of patients successfully reduced their regurgitation grade to mild after receiving treatment, indicating a substantial improvement in mitral regurgitation. The 5-year survival rate of patients reached 56.2%, which is quite remarkable within the heart failure patient population. Heart failure patients often face high mortality risks, and the Carillon system’s ability to significantly improve survival rates undoubtedly provides strong support for patients' health. Additionally, the system can substantially reduce heart failure hospitalization rates, which not only alleviates the financial burden and physical suffering of patients but also eases the strain on medical resources.

The Carillon system also excels in the flexibility of treatment. It does not hinder the patient's ability to receive other therapies in the future, a feature that makes it widely applicable in clinical practice. For patients with early-stage FMR, Carillon therapy can serve as a first-line treatment option. Early intervention helps control the progression of the condition and prevents further deterioration of the disease. Even if patients require other treatments later, such as medication or surgery, the implantation of the Carillon system will not cause interference. Doctors can flexibly develop personalized treatment plans based on the specific conditions of the patient. This flexibility allows the Carillon system to better meet the treatment needs of different patients, providing more comprehensive and precise medical services.

3. EMPOWER Trial: Pivotal Study Accelerates FDA Approval

1. Trial Objective

EMPOWER Trial as a Key Study of Cardiac Dimensions, Inc.: Carrying Significant Mission, Its Core Objective is to Fully Validate the Long-Term Safety and Effectiveness of the Carillon Mitral Contour System for Heart Failure Patients with Functional Mitral Regurgitation (FMR). Achieving This Goal is Crucial for Advancing the System’s Access to the U.S. Market. In the Current Medical Environment, the U.S. Market Has Strict Standards for the Approval of Innovative Medical Devices. Only Through Sufficient Clinical Trials Demonstrating That the Device Ensures Patient Safety and Effectively Improves Patient Conditions During Long-Term Use Can It Potentially Receive FDA Approval.

From the patient's perspective, FMR heart failure patients face severe health challenges. They not only endure various symptoms caused by heart failure, such as shortness of breath and fatigue, but also deal with the further deterioration of cardiac function due to mitral regurgitation. These patients urgently need a safe and effective treatment to improve their quality of life and extend their lifespan. The EMPOWER trial was conducted to meet this pressing need, aiming to provide a reliable treatment option for FMR heart failure patients.

2. Design Highlights

EMPOWER Trial: A Masterful Design with Multi-center, Randomized Controlled Methodology

In terms of patient selection, the trial included heart failure patients with both reduced and preserved ejection fractions, a move of significant importance. Ejection fraction is a crucial indicator of cardiac function, and heart failure patients with different ejection fractions exhibit variations in pathophysiological mechanisms, clinical manifestations, and treatment responses. Including both types of patients in the trial allows for a more comprehensive evaluation of the efficacy and safety of the Carillon system across different types of heart failure patients. This suggests that the Carillon system has the potential to offer treatment options to a broader population of FMR heart failure patients, breaking the limitations of previous treatment methods in patient selection and enabling more patients to benefit from this innovative therapy.

3. Expected Outcomes

If the EMPOWER trial is successful, its impact will be far-reaching. For patients with early-stage FMR, this will be a significant piece of good news. Currently, treatment options for early FMR are relatively limited. Traditional surgical treatments often come with high risks and significant trauma, which may be intolerable for some patients in poor physical condition. However, the Carillon system, as a minimally invasive interventional treatment, offers the advantages of minimal trauma and quick recovery. If validated by the EMPOWER trial, it will provide patients with early-stage FMR with a new and superior treatment option, filling the therapeutic gap in this field.

From a broader perspective, if the Carillon system is approved, it will also have a positive impact on the entire field of heart failure treatment. It will provide doctors with a new treatment method, enrich the options for treatment plans, and enable doctors to develop more personalized treatment strategies based on the specific conditions of patients. This will help improve the overall treatment level of heart failure, enhance patient prognosis, and bring new hope to many heart failure patients. It will also promote innovation and development in medical technology, encourage more companies to invest in research within the heart failure treatment field, and drive continuous progress in the industry.

4. Market and Commercialization: Initial Success in Global Layout

1. Regulatory Progress

In the stringent global regulatory environment for medical devices, the Carillon Mitral Contour System has successfully overcome numerous hurdles and achieved significant regulatory progress in multiple countries and regions, thanks to its outstanding safety and efficacy. In 2020, it obtained approval from the Australian Therapeutic Goods Administration (TGA), a strong endorsement of its safety and quality. Known for its rigorous medical regulatory system, Australia's TGA approval signifies that the Carillon system meets the country’s high standards for medical devices, ensuring safe and reliable treatment for patients in Australia.

On April 26, 2023, the Carillon system successfully obtained EU MDR certification. The EU MDR certification is extremely difficult to obtain, as it not only requires products to demonstrate outstanding performance in terms of safety and effectiveness but also imposes strict requirements on a company's quality management system, clinical evaluation, and other aspects. The fact that the Carillon system has achieved this certification fully demonstrates its excellence in technology, quality, and clinical value. This also lays a solid foundation for its further expansion in the European market, allowing more patients in European countries to benefit from this innovative therapy. Currently, the Carillon system has been included in the medical insurance reimbursement scope in multiple European countries, greatly improving the accessibility of the product and enabling more patients to afford this advanced treatment option.

2. Clinical Application

From the actual data of clinical applications, the Carillon system has demonstrated tremendous value worldwide. Globally, more than 1,500 patients have been treated with the Carillon system. These patients come from different regions and have varying disease characteristics, fully proving the broad applicability of the Carillon system. In the European market, the application of the Carillon system has achieved remarkable results, with an annual growth rate exceeding 30%, showing strong development momentum. An increasing number of European medical institutions have begun to adopt the Carillon system for treating patients with functional mitral regurgitation, which not only reflects the trust of doctors and patients in the system but also highlights its effectiveness and advantages in clinical practice.

In the United States, although the Carillon system is still in the research stage, patient recruitment for the pivotal EMPOWER trial has already begun, marking an important step for the Carillon system toward entering the U.S. market. Upon the successful completion of this trial, the Carillon system is expected to gain approval for marketing in the United States, bringing new hope to a large number of heart failure patients in the country. With its vast healthcare market and a significant population of heart failure patients, the entry of the Carillon system into the U.S. market will greatly expand its commercial reach, providing treatment options for more patients.

5. Industry Response: Dual Recognition from Capital and Experts

1. Investor Evaluation

As the lead investor in this financing round, Steve Plachtyna from Ally Bridge Group (Huiqiao Capital) highly praised Cardiac Dimensions, referring to it as a "breakthrough in heart failure treatment." He stated: "We are thrilled to lead this financing, which will help support Cardiac Dimensions’ significant progress in treating FMR heart failure patients. We have been deeply impressed by the company’s advancements in clinical work and its expansion of commercial sales outside the U.S. over the past few years. This financing will provide funding for both areas and accelerate their progress." From Steve Plachtyna’s comments, it is evident that Ally Bridge Group has great confidence in the future development of Cardiac Dimensions. They recognize the company’s achievements in clinical research, considering it to offer a new and effective approach for treating FMR heart failure patients. The company’s ability to expand commercial sales has also been acknowledged by Ally Bridge Group, indicating that the company not only holds an advantage in technology development but also possesses strong capabilities in market promotion and commercial operations. The support from Ally Bridge Group will provide Cardiac Dimensions with additional resources and strategic guidance, helping it achieve greater breakthroughs in the field of heart failure treatment.

2. Expert Opinions

Cardiac Dimensions President and CEO Rick Wypych Emphasizes the Advantages of the Carillon System from a Professional Perspective. He noted that the Carillon system is "safe, simple, and effective," three characteristics that make it stand out among many heart failure treatment options. Safety is the primary consideration for medical devices, and the Carillon system, through its unique design and technology, avoids damage to the mitral valve leaflets, reduces surgical risks, and provides patients with reliable safety assurance. The simple operational process allows more medical institutions and doctors to perform related treatments, improving treatment accessibility. Effectiveness has been validated through extensive clinical research and practice, as it significantly reduces mitral regurgitation, improves cardiac function in patients, enhances quality of life, and extends survival.

Rick Wypych also emphasized that the Carillon system will reshape the landscape of FMR treatment. In traditional FMR treatment, patients often face issues such as limited treatment options, high surgical risks, and unsatisfactory treatment outcomes. The emergence of the Carillon system brings new hope to FMR treatment. It provides an entirely new first-line treatment option for early-stage FMR patients, breaking through the limitations of traditional treatments. As the Carillon system continues to be promoted and applied, it is expected to change how doctors and patients perceive FMR treatment, driving the entire field toward safer, more effective, and minimally invasive directions.

6. Future Outlook: From Innovation to Inclusiveness

1. Technology Iteration

Cardiac Dimensions, Inc. is not content with its current achievements but is actively committed to the continuous innovation and iteration of technology. The company has formulated a clear plan dedicated to developing the next generation of Carillon products. In terms of the delivery system, an optimization upgrade is planned. Although the existing delivery system already offers the advantage of minimally invasive procedures, there is still room for improvement. The next-generation delivery system will further enhance operational precision, allowing doctors to place the device more accurately at the target location. This will reduce errors during surgery, increase the success rate of operations, and lower surgical risks. It will also improve the convenience of delivery, shorten operation time, and alleviate patient discomfort during surgery.

In terms of expanding indications, the company has more ambitious goals. Currently, the Carillon system is mainly used for heart failure patients with early functional mitral regurgitation. In the future, the company hopes to expand its indications to more complex cases. For example, for patients with more severe conditions and more complicated damage to cardiac structure and function, if the Carillon system can play a role, it will bring new hope to these patients. This requires the company to continuously make breakthroughs in technology research and development, deeply study the pathophysiological mechanisms of different types of patients, and develop more targeted treatment plans. By cooperating with research institutions and medical institutions, conducting more clinical trials, and accumulating more data and experience, a solid theoretical and practical foundation can be provided for the expansion of indications.

2. Patient Benefits

From the patient's perspective, Cardiac Dimensions has a clear goal: to enable more patients to benefit from the Carillon system through global expansion and health insurance negotiations. In terms of global expansion, the company will further increase its efforts to expand into international markets. Currently, the Carillon system has received regulatory approval and been commercialized in Australia and some European countries, but many patients in other countries and regions still do not have access to this innovative therapy. The company plans to collaborate with local medical institutions and distributors to establish a broader sales and service network, promoting the Carillon system to more countries and regions. This will not only help increase the company’s market share but, more importantly, allow more heart failure patients to have the opportunity to receive treatment, improving their quality of life and extending their lifespan.

Medicare negotiations are also a key focus for the company. Currently, although the Carillon system has been reimbursed by Medicare in several countries in Europe, there are still many patients worldwide who cannot afford the treatment due to its high cost. The company will actively negotiate with health insurance departments in various countries to include the Carillon system in the reimbursement scope of more countries and regions. By reducing the out-of-pocket expenses for patients, the accessibility of the treatment can be improved, allowing more patients to afford this advanced treatment option. This requires the company to continuously strive in terms of product quality, efficacy, and cost control, demonstrating the value and advantages of the Carillon system to health insurance departments in order to gain their recognition and support.

3. Industry Impact

From an industry perspective, the development of Cardiac Dimensions will have a profound impact on the field of transcatheter mitral valve repair technology. It will drive the entire technical field towards diversification. Currently, transcatheter mitral valve repair technology is mainly focused on edge-to-edge repair, while the emergence of the Carillon system brings new ideas and methods to this field. Its unique indirect annuloplasty creates differentiated competition with edge-to-edge repair. This competition will encourage other companies to increase R&D investment, develop more innovative technologies and products, and promote overall technological progress in the industry. The mutual learning and integration between different technologies will also provide patients with more treatment options, allowing doctors to choose the most suitable treatment plan based on the specific condition of the patient, thereby improving treatment outcomes.

The success of Cardiac Dimensions, Inc. will also inspire more companies to invest in the research and development of heart failure treatments. With the intensification of population aging, the number of heart failure patients continues to increase, driving a growing demand for effective treatment methods. The success of Cardiac Dimensions, Inc. in technological innovation, clinical research, and commercialization will set an example for other companies, attracting more funding, talent, and technology into the field. This will promote the overall prosperity of the industry, accelerate the research, development, and application of new technologies and products, and bring greater benefits to heart failure patients.